Q2 Solutions operates one of the world’s largest and most respected bioanalytical laboratory networks. From 20+ years of experience we have developed numerous robust methods used to deliver the vital data you need. Beyond those listed below we can also develop customized methods to meet your specific challenge.
Azithromycin | Ritonavir |
Chloroquine, hydroxychloroquine, and desethylhydroxychloroquine |
Tocaticinib |
Remdesivir | Tenofovir |
Compound/Metabolite | Range | Extraction Volume |
Matrix/Anticoagulant |
---|---|---|---|
Acyclovir; Valaciclovir | 10 – 1000 ng/mL | 50 μL | Human plasma/K3EDTA |
Amlodipine | 0.05 – 5 ng/mL | 20 μL | Human plasma/K2EDTA |
D-Amphetamine; L-Amphetamine (chiral) | 0.5 – 75 ng/mL | 200 μL | Human plasma/sodium EDTA |
Amphetamine (achiral) | 0.5 – 200 ng/mL | 100 μL | Human plasma/sodium EDTA |
Aprepitant | 10 – 10,000 ng/mL | 50 μL | Human plasma/K2EDTA |
Asenapine and Desmethylasenapine | 0.02 – 20 ng/mL | 200 μL | Human plasma/K2EDTA |
Atorvastatin; o-Hydroxyatorvastatin; p-Hydroxyatorvastatin | 0.25 – 25 ng/mL | 200 μL | Human plasma/sodium heparin and K3EDTA |
Available Soon Azithromycin |
1-1000 ng/mL |
20 μL |
Human plasma/K2EDTA |
Bortezomib | 0.1 – 25 ng/mL | 50 or 100 μL | Human plasma/K2EDTA, K3EDTA, and sodium heparin |
Available soon Budesonide |
1 – 500 pg/mL |
500 μL |
Human plasma/K2EDTA |
Bupropion; Hydroxybupropion | 0.1 – 100 ng/mL | 100 μL | Human plasma/K2EDTA |
Caffeine; Paraxanthine | 20 – 20,000 ng/mL | 100 μL | Human plasma/K2EDTA (surrogate matrix Bovine Serum Albumin (BSA) Phosphate Buffered Saline (PBS)) |
Capecitabine; 5'-DFCR/ 5'-DFUR/ 5-FU/ FBAL |
10 – 5000 ng/mL 50 – 25,000 ng/mL 2 – 1000 ng/mL 15 – 7500 ng/mL |
200 μL | Human plasma/sodium EDTA and K3EDTA |
Capecitabine/ 5-Fluorouracil |
10 – 5000 ng/mL 2 – 1000 ng/mL |
200 μL | Human plasma/K3EDTA |
Carbamazepine/ Carbamazepine 10,11-epoxide |
20 – 5000 ng/mL 20 – 500 ng/mL |
50 μL | Human plasma/sodium EDTA |
Available soon Chloroquine/Hydroxychloroquine/Desethyl-hydroxychloroquine |
1-500 ng/mL |
20 μL |
Human plasma/K2EDTA |
Clopidogrel/ Clopidogrel Acid/ Clopidogrel Active Metabolite (H4 diastereomer) |
0.05 – 25 ng/mL 5 – 5000 ng/mL 0.05 – 50 ng/mL |
100 μL | Human plasma/K2EDTA |
Clopidogrel Active Metabolite (H4 diastereomer only) | 0.0706 – 70.6 ng/mL | 200 μL | Human plasma/K2EDTA |
Cyclosporine A | 1 – 1000 ng/mL | 20 μL | Human blood/K2EDTA |
Cytarabine | 25 – 1000 ng/mL | 20 μL | Human plasma/sodium heparin |
Cytarabine/ Ara-Uridine |
0.5 – 1000 ng/mL 2 – 1000 ng/mL |
100 μL | Human plasma/K2EDTA |
Cytarabine/ Ara-Uridine |
20 – 20,000 ng/mL 50 – 50,000 ng/mL |
100 μL | Human plasma/K2EDTA |
Danazol | 0.5 – 500 ng/mL | 100 μL | Human plasma/K2EDT |
Desipramine/2-Hydroxydesipramine | 0.25 – 100 ng/mL | 20 μL | Human plasma/K2EDTA |
Daunorubicin; Daunorubicinol | 1 – 500 ng/mL | 100 μL | Human plasma/K2EDTA |
Decitabine | 0.5 – 500 ng/mL | 50 μL | Human plasma/K2EDTA |
Dextromethorphan/ Dextrorphan |
0.01 – 5 ng/mL 0.5 – 250 ng/mL |
100 μL |
Human plasma/K2EDTA |
Digoxin |
0.05 – 5 ng/mL |
200 μL |
Human serum Human plasma/K2EDTA |
Digoxin | 0.1 – 20 ng/mL | 200 μL | Human serum |
Digoxin | 1 – 200 ng/mL | 200 μL | Human urine |
Digoxin | 5 – 1000 ng/mL | 100 μL | Human urine |
Docetaxel | 1 – 2500 ng/mL | 200 μL | Human plasma/K2EDTA |
Available Soon Doxorubicin |
1 – 500 ng/mL |
50 μL |
Human plasma/K2EDTA |
Duloxetine/ Atomoxetine; S,S-Reboxetine |
0.2 – 200 ng/mL 0.5 – 500 ng/mL |
50 μL | Human plasma/K3EDTA |
Available Soon Entecavir |
25 – 15,000 pg/mL |
1000 μL |
Human urine |
Available Soon Entecavir |
25 – 20,000 pg/mL |
200 μL |
Human plasma/K2EDTA |
Epinephrine | 0.5 – 10 ng/mL | 100 μL | Human plasma/K2EDTA |
Erlotinib | 1 – 3000 ng/mL | 50 μL | Human plasma/sodium EDTA |
Available Soon Estriol |
5 – 5000 pg/mL |
500 μL |
Human plasma/K2EDTA |
5-Fluorouracil (5-FU) | 2 – 10,000 ng/mL | 100 μL | Human plasma/sodium EDTA |
5-Fluorouracil (5-FU) | 10 – 10,000 ng/mL | 100 μL | Human plasma/sodium EDTA and K2EDTA |
Fenofi bric Acid | 20 – 10000 ng/mL | 100 μL | Human plasma/sodium EDTA |
Fluconazole | 10 – 10,000 ng/mL | 20 μL | Human plasma/K2EDTA |
Flurbiprofen | 10 – 5000 ng/mL | 20 μL | Human plasma/K2EDTA |
Available Soon Fluticazone/Salmeterol |
5 – 200 pg/mL |
200 μL |
Human plasma/K2EDTA |
Gemcitabine | 10 – 10,000 ng/mL | 25 μL | Human plasma/lithium heparin |
Gemcitabine; 2',2'-Difluorodeoxyuridine | 10 – 10,000 ng/mL | 20 μL | Human plasma/lithium heparin |
Glyburide (total) | 1 – 250 ng/mL | 200 μL | Human plasma/sodium heparin |
Imatinib/ N-Desmethyl Imatinib |
100 – 10,000 ng/mL 50 – 5000 ng/mL |
50 μL | Human plasma/K2EDTA |
Itraconazole; Hydroxy Itraconazole | 1 – 1000 ng/mL | 20 μL | Human plasma/K2EDTA |
Ketoconazole | 10 – 10,000 ng/mL | 20 μL | Human plasma/K2EDTA |
Lamivudine (as part of Combivir®) | 2 – 1000 ng/mL | 200 μL | Human plasma/sodium heparin |
Lamivudine (as part of Combivir®) | 2 – 1000 ng/mL | 200 μL | Human urine |
Lovastatin; Lovastatin Acid | 0.25 – 100 ng/mL | 500 μL | Human plasma/sodium heparin |
Lovastatin; Lovastatin Acid | 0.25 – 125 ng/mL | 100 μL | Human plasma/K2EDTA |
Lumefantrine | 50 – 20,000 ng/mL | 50 μL | Human plasma/K2EDTA |
Metformin | 10 – 2000 ng/mL | 20 μL | Human plasma/sodium heparin |
Methotrexate (Low Range)/ 7-Hydroxymethotrexate |
0.25 – 200 ng/mL 1 – 120 ng/mL |
200 μL | Human plasma/lithium heparin and K2EDTA |
Methotrexate (Low Range)/ 7-Hydroxymethotrexate |
1 – 1000 ng/mL 1 – 150 ng/mL |
200 μL | Human plasma/lithium heparin and K2EDTA |
Methotrexate | 0.25 – 200 ng/mL | 200 μL | Human plasma/K2EDTA |
Methotrexate (Low Curve) | 50 – 1000 ng/mL | 20 μL | Human urine |
Methotrexate (High Curve)/ 7-Hydroxymethotrexate |
1000 – 50,000 ng/mL 50 – 1000 ng/mL |
20 μL | Human urine |
Methotrexate (Low Curve)/ 7-Hydroxymethotrexate |
50 – 10,000 ng/mL 20 – 1000 ng/mL |
20 μL | Human urine |
Methylphenidate; α-Phenyl-α-(2-Piperidyl)Acetic Acid | 0.05 – 25 ng/mL | 100 μL | Human plasma/acid citrate dextrose |
Metoprolol; α-Hydroxymetoprolol | 0.500 – 250 ng/mL | 100 μL | Human plasma/K2EDTA |
Midazolam; 1ʹ-Hydroxymidazolam | 0.1 – 100 ng/mL | 100 μL | Human plasma/K2EDTA |
Midazolam; 1ʹ-Hydroxymidazolam | 0.1 – 100 ng/mL | 20 μL | Human plasma/sodium and lithium heparin |
Montelukast | 2 – 2000 ng/mL | 20 μL | Human plasma/sodium heparin and K2EDTA |
Montelukast/36-Hydroxy Montelukast | 2 – 2000 ng/mL | 20 μL | Human plasma/K2EDTA |
Moxifloxacin | 25 – 5000 ng/mL | 50 μL | Human plasma/K2EDTA, K3EDTA, sodium EDTA, sodium heparin, and lithium heparin |
Nisoldipine | 0.02 – 20 ng/mL | 100 μL | Human plasma/K2EDTA |
Omeprazole/ 5ʹ-Hydroxyomeprazole; Omeprazole Sulfone |
1 – 500 ng/mL 0.5 – 250 ng/mL |
20 μL | Human plasma/K2EDTA and sodium heparin |
Paclitaxel; 6-Hydroxypaclitaxel | 10 – 5000 ng/mL | 200 μL | Human plasma/K2EDTA |
Paliperidone | 0.100 – 100 ng/mL | 100 μL | Human plasma/K2EDTA |
Paroxetine | 0.025 – 25 ng/mL | 50 μL | Human plasma/K2EDTA |
Pemetrexed | 10 – 5000 ng/mL | 50 μL | Human plasma/K2EDTA |
Available Soon Phenytoin |
20 – 20,000 ng/mL |
20 μL |
Human plasma/K2EDTA |
Available Soon Remdesivir/Active Metabolite GS-441524 |
5-5000 ng/mL |
50 μL |
Treated Human plasma/K2EDTA |
Repaglinide | 0.01 – 20 ng/mL | 50 μL | Human plasma/sodium heparin |
Rifampicin (Rifampin) | 10 – 5000 ng/mL | 100 μL | Human plasma/K2EDTA |
Risperidone | 0.1 – 100 ng/mL | 50 μL | Human plasma/K2EDTA |
Ritonavir | 10 – 5000 ng/mL | 50 μL | Human plasma/K3EDTA |
Rivastigmine | 0.1 – 30 ng/mL | 100 μL | Human plasma/potassium oxalate/sodium fluoride |
Rosiglitazone | 5 – 3000 ng/mL | 25 μL | Human plasma/K3EDTA |
Rosuvastatin/ Rosuvastatin Lactone; N-Desmethyl Rosuvastatin |
0.5 – 100 ng/mL 0.5 – 50 ng/mL |
100 μL | Human plasma/K2EDTA |
Sildenafil | 1 – 1000 ng/mL | 50 μL | Human plasma/K2EDTA |
Sildenafil; N-Desmethyl Sildenafil | 1 – 1000 ng/mL | 50 μL | Human plasma/K2EDTA |
Simvastatin; Simvastatin Acid | 0.1 – 30 ng/mL | 200 μL | Human plasma/K3EDTA |
Sunitinib/ Desethyl Sunitinib |
0.1 – 60 ng/mL 0.1 – 20 ng/mL |
20 μL | Human plasma/K2EDTA |
Telaprevir | 50 – 20,000 ng/mL | 100 μL | Human plasma/K2EDTA |
Tenofovir | 2 – 1000 ng/mL | 100 μL | Human plasma/K2EDTA |
Tolbutamide; 4-Hydroxytolbutamide | 50 – 50,000 ng/mL | 20 μL | Human plasma/K2EDTA |
Tolterodine; 5-Hydroxymethyl Tolterodine | 0.2 – 50 ng/mL | 100 μL | Human plasma/sodium heparin |
Valproic Acid | 1 – 100 μg/mL | 100 μL | Human serum |
Verapamil; Norverapamil | 0.2 – 200 ng/mL | 50 μL | Human plasma/K2EDTA |
R-Warfarin; S-Warfarin (chiral) | 0.1 – 10 ng/mL | 250 μL | Human PFF (non-protein bound) |
R-Warfarin; S-Warfarin (chiral) | 1 – 2500 ng/mL | 100 μL | Human plasma (total)/sodium heparin |
Zidovudine (as part of Combivir®) | 2 – 1000 ng/mL | 200 μL | Human plasma/sodium heparin |
Zidovudine (as part of Combivir®) | 2 – 1000 ng/mL | 200 μL | Human urine |
Ziprasidone | 0.5 – 150 ng/mL | 200 μL | Human plasma/sodium heparin |
Biomarker/ Analyte on ELISA platform |
Quantitation Range | Assay Volume |
Minimum Required Dilution (MRD) |
Matrix |
---|---|---|---|---|
HER-2/neu | 2.5 – 35 ng/mL | 10 μL | 1:50 | Human serum |
β-NGF (free) | 1 – 500 pg/mL | 25 μL | 1:1 (no MRD) | Human serum |
IGF-1 (total) | 0.15 – 6 ng/mL | 20 μL | 1:100 (treated sample) | Human serum |
IGF-1 (free) | 0.15 – 6 ng/mL | 10 μL | 1:50 (untreated sample) | Human serum |
sECAD | 0.625 – 20 ng/mL | 20 μL | 1:20 | Human serum |
sEGFr | 12.5 – 300 ng/mL | 10 μL | 1:50 | Human serum |
VEGF | 50 – 1000 pg/mL | 100 μL | 1:2 | Human plasma/sodium citrate |
Biomarker Method Development and Validation Expertise | |||
---|---|---|---|
Amino Acids, Lipids, Neurotransmitters, Nucleotides, Hormones, Peptides, Proteins – immunoprecipitation, digestion, immunoaffinity LC/LC/nano LC/MS/MS | |||
Biomarker Non-Proprietary Methods | |||
Biomarker | Range | Volume Required | Matrix |
9 Essential Amino Acid Panel | 0.5 – 100 μg/mL | 50 μL | Human plasma/K2EDTA |
4β-Hydroxycholesterol | 2 – 300 ng/mL | 50 μL | Human plasma/K2EDTA |
β-Nerve Growth Factor (NGF) | 10 – 1280 pg/mL | 200 µL | Human serum |
Cholesterol | 0.75 – 3.5 mg/mL | 10 µL | Human plasma/K2EDTA |
Citrulline | 300 – 40,000 ng/mL | 20 µL | Human plasma/K2EDTA |
Digoxin | 0.05 – 5 ng/mL | 200 µL | Human plasma/K2EDTA |
7α-Hydroxy-4-cholesten-3-one (C4) | 2 – 250 ng/mL | 40 μL | Human serum |
Insulin | 40 – 1250 pg/mL | 350 μL | Human serum |
Kynurenine/ Tryptophan |
0.05 – 15 μg/mL 0.2 – 60 μg/mL |
20 μL | Human plasma/K3EDTA |
Rat Hepcidin | 2 – 500 ng/mL | 25 μL | Rat serum |